Over the next 10 years, the global dermatology therapeutics market is projected to double, soaring to $3.59bn in 2034, propelled forward by billion-dollar deals and strategic acquisitions highlight the sector’s accelerating growth, from inflammatory skin disease to aesthetic dermatology and rare conditions.
Leading pharma and biotech is doubling down on skin-focused innovation, with Gilead inking a $1.7 billion global inflammation deal with LEO Pharma, Organon’s $1.2 billion acquisition of Dermavant, while M&A activity in CDMO and imaging services continues to surge, like the Tergus-MedPharm merger and L’Oréal’s strategic stake in Galderma, reflect the full-spectrum opportunity for service providers across R&D and commercialization.
Top solutions needed:
Preclinical CROs: Provide in vitro and in vivo dermatology models to assess safety, skin irritation, barrier function, and drug penetration. Key solutions include 3D human skin models, topical formulation screening, and disease-specific efficacy studies for indications like psoriasis, AD, and acne.
Clinical CROs: Offer end-to-end trial management with dermatology expertise—site selection, dermatology-trained investigators, validated scoring systems (e.g., PASI, EASI), high-throughput photography, and patient recruitment for chronic and rare skin conditions.
Diagnostics & Imaging: Deliver non-invasive imaging and digital tools for objective skin assessment. Solutions include confocal microscopy, dermoscopy, OCT, AI-based image analysis, and biomarker-driven diagnostics to track treatment response and support endpoint validation.
CDMOs: Specialize in development and GMP manufacturing of topical, transdermal, and injectable dermatology products. Services include formulation optimization (creams, gels, ointments), scale-up, stability studies, and regulatory support.
Metabolomic & Proteomic Companies: Enable biomarker discovery and mechanism-of-action studies via skin-specific omics profiling. Solutions include analysis of inflammatory cytokines, skin lipid metabolism, and protein expression changes in response to treatment.
Why Partner?
Showcase your solutions via a speaking slot or technology spotlight
Network 1:1 with decision-makers actively building pipelines in dermatology
Build long-term relationships with companies investing in novel skin-targeted therapies
Who Will You Meet?
Previously Attending Companies Include:
